CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

CRISPR Therapeutics is the subject of strong buyout speculation after earning FDA approval for a breakthrough gene-editing ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the most oversold biotech stocks to invest in. Following the company’s third-quarter financial results, Oppenheimer reaffirmed its Outperform rating ...

Multiple analysts have issued price targets for $CRSP recently. We have seen 15 analysts offer price targets for $CRSP in the last 6 months, with a median target of ...

CRISPR Therapeutics CRSP reported a second-quarter 2025 loss of $2.40 per share, which was wider than the year-ago period’s loss of $1.49. The increased loss was attributable to the payment of $96.3 ...

RGA Investment Advisors, an investment management company, has released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The second quarter-end figures concealed ...

CRISPR Therapeutics AG remains a pioneering gene editing company, with Casgevy's slow commercial ramp and robust pipeline driving long-term potential. Despite Casgevy's $2.2M list price and broad ...

Spire Wealth Management reduced its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 15.2% during the 1st quarter, according to the company in its most recent 13F filing with the ...